Clinical trial · Interventional
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00086034CI-TRIAL-00000729completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Motexafin gadolinium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Clinical response rate
Secondary outcomes (3)
- measure
- Progression-free survival
- measure
- Duration of clinical response
- measure
- Safety and tolerability
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥ 18 years old * Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosa-associated lymphoid tissue (MALT) types * Failed ≥ 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy * ECOG performance status score either 0 or 1 * Willing and able to provide written informed consent Exclusion Criteria: Laboratory values of: * Platelet count \< 50,000/µL * AST or ALT \> 2 x the upper limit of normal (ULN) * Total bilirubin \> 2 x ULN * Creatinine \> 2.0 mg/dL and * Greater than three prior regimens (where a regimen is defined as a treatment for NHL given after disease progression) * Uncontrolled hypertension * Known history of porphyria, G6PD deficiency, HIV
References
Publications (0)
Data not yet available
No reference posted for this study.